Kingfisher Capital’s AbbVie ABBV Stock Holding History

Kingfisher Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$3.69M	Sell	18,705 -342	-2%	-$63.8K	0.85%	42
2024 Q2	$3.27M	Sell	19,047 -192	-1%	-$31.8K	0.76%	45
2024 Q1	$3.5M	Sell	19,239 -586	-3%	-$101K	0.84%	44
2023 Q4	$3.07M	Buy	19,825 +9,995	+102%	+$1.46M	0.8%	47
2023 Q3	$1.47M	Sell	9,830 -220	-2%	-$32.3K	0.4%	74
2023 Q2	$1.35M	Buy	10,050 +189	+2%	+$27.7K	0.35%	82
2023 Q1	$1.57M	Buy	9,861 +38	+0.4%	+$5.81K	0.41%	77
2022 Q4	$1.59M	Buy	9,823 +31	+0.3%	+$4.75K	0.42%	75
2022 Q3	$1.31M	Buy	9,792 +2,693	+38%	+$386K	0.36%	85
2022 Q2	$1.09M	Buy	7,099 +42	+0.6%	+$6.42K	0.31%	92
2022 Q1	$1.14M	Buy	7,057 +105	+2%	+$15.3K	0.3%	97
2021 Q4	$941K	Sell	6,952 -65	-0.9%	-$7.68K	0.22%	111
2021 Q3	$756K	Buy	7,017 +154	+2%	+$17.6K	0.2%	110
2021 Q2	$773K	Buy	6,863 +249	+4%	+$28K	0.2%	115
2021 Q1	$716K	Buy	6,614 +295	+5%	+$31.6K	0.2%	118
2020 Q4	$677K	Buy	6,319 +595	+10%	+$57.2K	0.21%	118
2020 Q3	$501K	Buy	5,724 +108	+2%	+$10.2K	0.18%	121
2020 Q2	$551K	Buy	5,616 +53	+1%	+$4.67K	0.24%	102
2020 Q1	$424K	Buy	5,563 +51	+0.9%	+$4.34K	0.22%	113
2019 Q4	$488K	Sell	5,512 -1,168	-17%	-$97K	0.23%	113
2019 Q3	$506K	Buy	6,680 +4	+0.1%	+$274	0.3%	99
2019 Q2	$485K	Buy	6,676 +70	+1%	+$5.5K	0.3%	86
2019 Q1	$532K	Sell	6,606 -1,903	-22%	-$156K	0.34%	83
2018 Q4	$784K	Sell	8,509 -578	-6%	-$50.8K	0.56%	64
2018 Q3	$859K	Buy	9,087 +61	+0.7%	+$5.79K	0.46%	71
2018 Q2	$836K	Buy	9,026 +2,127	+31%	+$208K	0.53%	71
2018 Q1	$653K	Sell	6,899 -1,885	-21%	-$207K	0.42%	81
2017 Q4	$849K	Sell	8,784 -166	-2%	-$15.6K	0.54%	71
2017 Q3	$795K	Buy	8,950 +297	+3%	+$22.6K	0.53%	74
2017 Q2	$627K	Sell	8,653 -1	-0%	-$67	0.42%	77
2017 Q1	$564K	Sell	8,654 -546	-6%	-$34.3K	0.41%	81
2016 Q4	$576K	Sell	9,200 -183	-2%	-$11.2K	0.43%	84
2016 Q3	$592K	Buy	9,383 +1	+0%	+$65	0.41%	88
2016 Q2	$581K	Sell	9,382 -207	-2%	-$12.6K	0.38%	88
2016 Q1	$548K	Buy	9,589 +4	+0%	+$223	0.34%	93
2015 Q4	$568K	Sell	9,585 -11,581	-55%	-$667K	0.34%	100
2015 Q3	$1.15M	Buy	21,166 +45	+0.2%	+$2.93K	0.73%	62
2015 Q2	$1.42M	Sell	21,121 -759	-3%	-$49.6K	0.82%	53
2015 Q1	$1.28M	Buy	21,880 +497	+2%	+$30K	0.66%	71
2014 Q4	$1.4M	Buy	21,383 +330	+2%	+$20.8K	0.72%	69
2014 Q3	$1.22M	Sell	21,053 -59	-0.3%	-$3.28K	0.65%	74
2014 Q2	$1.19M	Sell	21,112 -2,517	-11%	-$132K	0.62%	77
2014 Q1	$1.22M	Sell	23,629 -96	-0.4%	-$4.85K	0.64%	69
2013 Q4	$1.25M	Sell	23,725 -48	-0.2%	-$2.36K	0.67%	66
2013 Q3	$1.06M	Buy	23,773 +119	+0.5%	+$5.28K	0.54%	77
2013 Q2	$978K	Buy	+23,654	New	+$1.03M	0.54%	76

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Kingfisher Capital's ABBV Position: Q3 2024 in Review

Kingfisher Capital reduced its AbbVie (ABBV) stake by 1.8% in Q3 2024, selling an estimated $63.8K and leaving 18,705 shares worth $3.69M. The position accounts for 0.85% of the portfolio, ranked #42.

Kingfisher Capital first reported a position in ABBV in Q2 2013 and has held it in 46 quarters since. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

Kingfisher Capital held 18,705 shares of AbbVie worth $3.69M as of Q3 2024.
Kingfisher Capital sold 342 AbbVie shares in Q3 2024, an estimated $63.8K.
AbbVie made up 0.85% of Kingfisher Capital's portfolio in Q3 2024, its #42 holding.
Kingfisher Capital first reported a position in AbbVie in Q2 2013 and has held it in 46 quarters since.
3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Kingfisher Capital's 13F filing for Q3 2024, filed 14 Nov 2024.